Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

被引：159

作者：

Reck, Martin ^{[1
]}

Schenker, Michael ^{[2
]}

Lee, Ki Hyeong ^{[3
]}

Provencio, Mariano ^{[4
]}

Nishio, Makoto ^{[5
]}

Lesniewski-Kmak, Krzysztof ^{[6
]}

Sangha, Randeep ^{[7
]}

Ahmed, Samreen ^{[8
]}

Raimbourg, Judith ^{[9
]}

Feeney, Kynan ^{[10
,11
]}

Corre, Romain ^{[12
]}

Franke, Fabio Andre ^{[13
]}

Richardet, Eduardo ^{[14
]}

Penrod, John R. ^{[15
]}

Yuan, Yong ^{[15
]}

Nathan, Faith E. ^{[15
]}

Bhagavatheeswaran, Prabhu ^{[15
]}

DeRosa, Michael ^{[16
]}

Taylor, Fiona ^{[16
]}

Lawrance, Rachael ^{[17
]}

Brahmer, Julie ^{[18
]}

机构：

[1] German Ctr Lung Res DZL, ARCN, LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany

[2] Cent Oncol Sf Nectarie, 23A Caracal St, Craiova 200347, Romania

[3] Chungbuk Natl Univ Hosp, 776,1 Sunhwan Ro, Cheongju 28644, Chungcheonbuk D, South Korea

[4] Univ Autonoma Madrid, Inst Invest Puerta Hierro, Hosp Puerta Hierro de Majadahonda, C Manuel de Falla 1, Madrid 28222, Majadahonda, Spain

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan

[6] Gdansk Med Univ, Oddzial Onkol Radioterapii Szpital, UI Powstania Styczniowego 1, PL-81519 Gdynia, Poland

[7] Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada

[8] Univ Hosp Leicester NHS Trust, Dept Infect, Leicester LE1 5WW, Leics, England

[9] Inst Cancerol Ouest, Ctr Rene Gauducheau, Blvd Jacques Monad, F-44805 Nantes, France

[10] Notre Dame Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[11] Edith Cowan Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[12] CHU Rennes, 2 Rue Henri le Guilloux, F-35033 Rennes, France

[13] Hosp Caridade Ijui, CACON, Av David Jose Martins, BR-98700000 Ijui, RS, Brazil

[14] IONC Univ Catolica Cordoba, Parana 560 2 Piso, RA-5000 Cordoba, Argentina

[15] Bristol Myers Squibb Co, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA

[16] Adelphi Values, 290 Congress St 7th Floor, Boston, MA 02210 USA

[17] Adelphi Values, Grimshaw Ln, Bollington SK10 5JB, Cheshire, England

[18] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1-G94, Baltimore, MD 21287 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷

关键词：

Antineoplastic agents; Carcinoma; Ipilimumab; Lung neoplasms; Nivolumab; Non-small-cell lung cancer; Platinum-doublet chemotherapy; Quality of life; Surveys and questionnaires; QUALITY-OF-LIFE; DOCETAXEL; SYMPTOMS; MULTICENTER;

D O I：

10.1016/j.ejca.2019.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the phase I I I CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; >= 10 mutations/megabase). Aim: To evaluate patient-reported outcomes (PROs) in this population. Methods: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. Results: In the high TMB population, PRO questionnaire completion rates were similar to 90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. Conclusion: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. (C) 2019 The Authors. Published by Elsevier Ltd.

引用

页码：137 / 147

页数：11

共 50 条

[1] Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
Borghaeit, H.
O'Byrnet, K. J.
Paz-Ares, L.
Ciuleanu, T. -E
Yu, X.
Pluzanski, A.
Nagrial, A.
Havel, L.
Kowalyszyn, R. D.
Valette, C. A.
Brahmer, J. R.
Reck, M.
Ramalingam, S. S.
Zhang, L.
Ntambwe, I.
Rabindran, S. K.
Nathan, F. E.
Balli, D.
Wu, Y. -L.
ESMO OPEN, 2023, 8 (06)
[2] Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hellmann, Matthew D.
Rizvi, Naiyer A.
Goldman, Jonathan W.
Gettinger, Scott N.
Borghaei, Hossein
Brahmer, Julie R.
Ready, Neal E.
Gerber, David E.
Chow, Laura Q.
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott A.
Geese, William J.
Agrawal, Shruti
Young, Tina C.
Li, Xuemei
Antonia, Scott J.
LANCET ONCOLOGY, 2017, 18 (01): : 31 - 41
[3] First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Reck, Martin
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Schenker, Michael
Audigier-Valette, Clarisse
Zurawski, Bogdan
Linardou, Helena
Otterson, Gregory A.
Salman, Pamela
Nishio, Makoto
Jimenez, Emmanuel de la Mora
Lesniewski-Kmak, Krysztof
Albert, Istvan
Ahmed, Samreen
Syrigos, Konstantinos
Penrod, John R.
Yuan, Yong
Blum, Steven, I
Nathan, Faith E.
Sun, Xiaowu
Moreno-Koehler, Alejandro
Taylor, Fiona
O'Byrne, Kenneth John
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 665 - 676
[4] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Scherpereel, Arnaud
Antonia, Scott
Bautista, Yolanda
Grossi, Francesco
Kowalski, Dariusz
Zalcman, Gerard
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Sun, Xiaowu
Lawrance, Rachael
Zhang, Xiaoqing
Daumont, Melinda J.
Bennett, Bryan
McKenna, Mike
Baas, Paul
LUNG CANCER, 2022, 167 : 8 - 16
[5] First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Ready, Neal
Hellmann, Matthew D.
Awad, Mark M.
Otterson, Gregory A.
Gutierrez, Martin
Gainor, Justin F.
Borghaei, Hossein
Jolivet, Jacques
Horn, Leora
Mates, Mihaela
Brahmer, Julie
Rabinowitz, Ian
Reddy, Pavan S.
Chesney, Jason
Orcutt, James
Spigel, David R.
Reck, Martin
O'Byrne, Kenneth John
Paz-Ares, Luis
Hu, Wenhua
Zerba, Kim
Li, Xuemei
Lestini, Brian
Geese, William J.
Szustakowski, Joseph D.
Green, George
Chang, Han
Ramalingam, Suresh S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 992 - +
[6] Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
Garon, Edward B.
Cho, Byoung Chul
Reinmuth, Niels
Lee, Ki Hyeong
Luft, Alexander
Ahn, Myung-Ju
Robinet, Gilles
Le Moulec, Sylvestre
Natale, Ronald
Schneider, Jeffrey
Shepherd, Frances A.
Garassino, Marina Chiara
Geater, Sarayut Lucien
Szekely, Zsolt Papai
Van Ngoc, Tran
Liu, Feng
Scheuring, Urban
Patel, Nikunj
Peters, Solange
Rizvi, Naiyer A.
CLINICAL LUNG CANCER, 2021, 22 (04) : 301 - +
[7] First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Reck, Martin
Ciuleanu, Tudor-Eliade
Cobo, Manuel
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurelia
Cheng, Ying
Sakai, Hiroshi
Paz-Ares, Luis
Lu, Shun
John, Thomas
Sun, Xiaowu
Moisei, Aniela
Taylor, Fiona
Lawrance, Rachael
Zhang, Xiaoqing
Sylvester, Judi
Yuan, Yong
Blum, Steven I.
Penrod, John R.
Carbone, David P.
EUROPEAN JOURNAL OF CANCER, 2023, 183 : 174 - 187
[8] Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Garon, Edward B.
Cho, Byoung Chul
Luft, Alexander
Alatorre-Alexander, Jorge
Geater, Sarayut Lucien
Kim, Sang-We
Ursol, Grygorii
Hussein, Maen
Lim, Farah Louise
Yang, Cheng-Ta
Araujo, Luiz Henrique
Saito, Haruhiro
Reinmuth, Niels
Medic, Nenad
Mann, Helen
Shi, Xiaojin
Peters, Solange
Mok, Tony
Johnson, Melissa
LUNG CANCER, 2023, 186
[9] Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
Bordoni, Rodolfo
Ciardiello, Fortunato
von Pawel, Joachim
Cortinovis, Diego
Karagiannis, Thomas
Ballinger, Marcus
Sandier, Alan
Yu, Wei
He, Pei
Matheny, Christina
Felizzi, Federico
Rittmeyer, Achim
CLINICAL LUNG CANCER, 2018, 19 (05) : 441 - +
[10] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Cella, David
Gruenwald, Viktor
Escudier, Bernard
Hammers, Hans J.
George, Saby
Nathan, Paul
Grimm, Marc-Oliver
Rini, Brian, I
Doan, Justin
Ivanescu, Cristina
Paty, Jean
Mekan, Sabeen
Motzer, Robert J.
LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310

← 1 2 3 4 5 →